DK0751709T3 - Anvendelse af Bcl-2 til fremstilling af lægemidler til terapeutisk behandling og forebyggelse af sygdomme - Google Patents
Anvendelse af Bcl-2 til fremstilling af lægemidler til terapeutisk behandling og forebyggelse af sygdommeInfo
- Publication number
- DK0751709T3 DK0751709T3 DK94919263T DK94919263T DK0751709T3 DK 0751709 T3 DK0751709 T3 DK 0751709T3 DK 94919263 T DK94919263 T DK 94919263T DK 94919263 T DK94919263 T DK 94919263T DK 0751709 T3 DK0751709 T3 DK 0751709T3
- Authority
- DK
- Denmark
- Prior art keywords
- bcl
- drugs
- diseases
- prevention
- manufacture
- Prior art date
Links
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 title 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 title 1
- 230000006806 disease prevention Effects 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/39—Pancreas; Islets of Langerhans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/02—Animal zootechnically ameliorated
- A01K2267/025—Animal producing cells or organs for transplantation
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Environmental Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Animal Husbandry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biodiversity & Conservation Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Psychology (AREA)
- Microbiology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/066,556 US5550019A (en) | 1993-05-26 | 1993-05-26 | Methods of identifying compounds which alter apoptosis |
PCT/US1994/005980 WO1994027426A1 (en) | 1993-05-26 | 1994-05-26 | Methods of using bcl-2 for the therapeutic treatment and prevention of diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0751709T3 true DK0751709T3 (da) | 2002-03-04 |
Family
ID=22070248
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK94919263T DK0751709T3 (da) | 1993-05-26 | 1994-05-26 | Anvendelse af Bcl-2 til fremstilling af lægemidler til terapeutisk behandling og forebyggelse af sygdomme |
Country Status (10)
Country | Link |
---|---|
US (4) | US5550019A (ja) |
EP (2) | EP1130087A3 (ja) |
JP (2) | JP3704348B2 (ja) |
AT (1) | ATE204704T1 (ja) |
CA (1) | CA2163439C (ja) |
DE (1) | DE69428130T3 (ja) |
DK (1) | DK0751709T3 (ja) |
ES (1) | ES2160124T3 (ja) |
PT (1) | PT751709E (ja) |
WO (1) | WO1994027426A1 (ja) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6841541B1 (en) | 1992-02-21 | 2005-01-11 | The Trustees Of The University Of Pennsylvania | Regulation of BCL-2-gene expression |
US5831066A (en) * | 1988-12-22 | 1998-11-03 | The Trustees Of The University Of Pennsylvania | Regulation of bcl-2 gene expression |
US5539085A (en) * | 1993-08-20 | 1996-07-23 | Onyx Pharmaceuticals, Inc. | Bcl-2 and R-ras complex |
US6231852B1 (en) | 1993-11-18 | 2001-05-15 | The Regents Of The University Of California | Method for reducing BCL-2 expressing cells resistance to death |
FR2739561B1 (fr) * | 1995-10-06 | 1997-12-26 | Inst Nat Sante Rech Med | Utilisation d'un vecteur assurant l'expression ou l'augmentation transitoire de l'activite bc1-2 |
US5972622A (en) * | 1996-02-08 | 1999-10-26 | Desjardins; Louise | Method of detecting apoptosis using an anti-human GP46 monoclonal anti-body |
US5744460A (en) * | 1996-03-07 | 1998-04-28 | Novartis Corporation | Combination for treatment of proliferative diseases |
AUPN896596A0 (en) * | 1996-03-27 | 1996-04-26 | Walter And Eliza Hall Institute Of Medical Research, The | Therapeutic molecules |
CA2295500A1 (en) * | 1996-07-12 | 1998-01-22 | Massachusetts Institute Of Technology | Methods of controlling axonal growth |
US6558900B2 (en) | 1996-07-12 | 2003-05-06 | Emory University | Regulation of apoptosis and in vitro model for studies thereof |
CA2260766A1 (en) * | 1996-07-12 | 1998-01-22 | Emory University | Regulation of apoptosis and in vitro model for studies thereof |
US6180402B1 (en) | 1996-11-20 | 2001-01-30 | Qlt Inc. | Method for inhibiting apoptosis induced by photodynamic therapy using a cysteine or serine protease inhibitor |
EP0975781A1 (en) | 1997-04-01 | 2000-02-02 | The General Hospital Corporation | Molecular marker for muscle stem cells |
US7238662B2 (en) * | 1997-12-18 | 2007-07-03 | Ambryx Biotechnology, Inc. | Alpha 2HS glycoprotein for treatment of cancer and a method for preparation thereof |
US6720311B2 (en) | 1997-12-18 | 2004-04-13 | David Tsai | Polypeptide for the treatment of cancer and a method for preparation thereof |
US6737402B2 (en) | 1997-12-18 | 2004-05-18 | David Tsai | Method of preparing fetuin to induce apoptosis |
US20010041342A1 (en) * | 1998-04-01 | 2001-11-15 | The General Hospital Corporation, A Massachusetts Corporation | Molecular marker for muscle stem cells |
US7381413B1 (en) * | 1998-04-17 | 2008-06-03 | University Of Vermont And State Agricultural College | Methods and products related to metabolic interactions in disease |
WO2000002578A1 (fr) * | 1998-07-10 | 2000-01-20 | Meiji Milk Products Co., Ltd. | Remedes contre les maladies liees a l'apoptose |
AU5789500A (en) * | 1999-07-09 | 2001-01-30 | Burnham Institute, The | A method for determining the prognosis of cancer patients by measuring levels ofbag expression |
US6277974B1 (en) * | 1999-12-14 | 2001-08-21 | Cogent Neuroscience, Inc. | Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death |
US6773894B1 (en) * | 2000-01-21 | 2004-08-10 | Biochain Institute, Inc. | Isolation and extraction of subcellularly compartmentalized protein |
WO2001052639A1 (en) | 2000-01-21 | 2001-07-26 | Beth Israel Deaconess Medical Center | Use of pro-apoptotic factors in treatment of atherosclerosis |
US20030044413A1 (en) * | 2000-08-15 | 2003-03-06 | Regents Of The University Of Minnesota | Methods of limiting apoptosis of cells |
US7795232B1 (en) | 2000-08-25 | 2010-09-14 | Genta Incorporated | Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers |
US7419825B2 (en) * | 2001-04-20 | 2008-09-02 | Children's Hospital Of Orange County | Isolation of neural stem cells using gangliosides and other surface markers |
DE10228187A1 (de) * | 2002-06-24 | 2004-01-22 | MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH | Testsystem zum Nachweis von Krebserkrankungen |
US8017323B2 (en) * | 2003-03-26 | 2011-09-13 | President And Fellows Of Harvard College | Free reactant use in nucleic acid-templated synthesis |
CA2575591A1 (en) | 2003-08-08 | 2005-02-17 | Yuji Shino | A pharmaceutical composition for treatment of cancers |
JP2005305107A (ja) * | 2004-03-25 | 2005-11-04 | Sei Matsuoka | 価値的情報値の測定装置およびこれを使用した測定方法 |
US7531327B2 (en) * | 2004-07-23 | 2009-05-12 | Immunomedics, Inc. | Methods and compositions for increasing longevity and protein yield from a cell culture |
US7537930B2 (en) | 2004-07-23 | 2009-05-26 | Immunomedics, Inc. | Mammalian cell lines for increasing longevity and protein yield from a cell culture |
US7608425B2 (en) * | 2004-07-23 | 2009-10-27 | Immunomedics, Inc. | Methods for protein expression in mammalian cells in serum-free medium |
US20060159681A1 (en) * | 2004-12-14 | 2006-07-20 | Functional Neuroscience Inc. | Compositions and methods to inhibit cell loss by using inhibitors of BAG |
US20070092947A1 (en) * | 2005-10-20 | 2007-04-26 | Immunomedics, Inc. | Methods and compositions for increasing longevity and protein yield from a cell culture |
WO2007067032A1 (en) | 2005-12-09 | 2007-06-14 | Academisch Medisch Cemtrum Bij De Universiteit Van Amsterdam | Means and methods for influencing the stability of cells |
AU2006323315B2 (en) | 2005-12-09 | 2014-02-20 | Academisch Medisch Centrum Bij De Universiteit Van Amsterdam | Means and methods for influencing the stability of antibody producing cells |
ITMI20060384A1 (it) * | 2006-03-03 | 2007-09-04 | Umberto Cornelli | Composizioni comprendenti chitosano atte al trattamento terapeutico complessivo o alla prevenzione complessiva della sindrome metabolica |
US20100189802A1 (en) * | 2007-08-21 | 2010-07-29 | Scott And White Memorial Hospital And Scott, Sherwood, And Brindley Foundation | Method for treatment of vascular hyperpermeability |
US20090069223A1 (en) * | 2007-08-21 | 2009-03-12 | Childs Ed W | Method for treatment of vascular hyperpermeability |
US8192420B2 (en) | 2007-12-20 | 2012-06-05 | Acclarent, Inc. | Iontophoresis methods |
US8497092B2 (en) | 2008-04-03 | 2013-07-30 | Tsumura & Co. | Method of bioassaying yokukansan |
WO2009126764A1 (en) | 2008-04-11 | 2009-10-15 | Cytotech Labs, Llc | Methods and use of inducing apoptosis in cancer cells |
WO2009141915A1 (ja) | 2008-05-23 | 2009-11-26 | 有限会社西原 | Bcl-2蛋白発現剤、アポトーシス抑制剤および表皮細胞の紫外線dna障害防止剤 |
CA2768207C (en) | 2009-07-15 | 2019-12-03 | Aimm Therapeutics B.V. | Means and methods for producing high affinity antibodies |
DK2646466T3 (en) | 2010-12-02 | 2017-06-06 | Aimm Therapeutics Bv | METHODS AND METHODS FOR MANUFACTURING HIGH EFFICIENCY ANTIBODIES |
MX2014001073A (es) | 2011-07-25 | 2014-03-21 | Acclarent Inc | Sistema y metodo personalizable para anestesiar la membrana timpanica. |
AU2015211480B2 (en) | 2014-01-31 | 2020-05-14 | Kling Biotherapeutics B.V. | Means and methods for producing stable antibodies |
US10016304B2 (en) | 2015-07-16 | 2018-07-10 | Tusker Medical, Inc. | Earplug assembly for iontophoresis system |
US20220204575A1 (en) * | 2019-04-23 | 2022-06-30 | The Regents Of The University Of California | Modulating survival of therapeutic cells and methods, cells and nucleic acids related thereto |
AU2022325943A1 (en) * | 2021-08-11 | 2024-02-29 | The Trustees Of The University Of Pennsylvania | Modulation of bcl-2 to enhance chimeric antigen receptor cancer immunotherapy efficacy |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4271145A (en) * | 1979-10-22 | 1981-06-02 | The Massachusetts General Hospital | Process for producing antibodies to hepatitis virus and cell lines therefor |
US5202429A (en) * | 1986-07-09 | 1993-04-13 | The Wistar Institute | DNA molecules having human BCL-2 gene sequences |
US4997764A (en) | 1987-04-23 | 1991-03-05 | New York University | Transformation of human B-lympocytes with Epstein Barr virus and c-myc containing vectors |
US5024947A (en) | 1987-07-24 | 1991-06-18 | Cetus Corporation | Serum free media for the growth on insect cells and expression of products thereby |
US5149628A (en) * | 1989-11-15 | 1992-09-22 | Temple University | Methods for detecting bcl-3 gene in human leukemias |
US5328844A (en) | 1990-05-09 | 1994-07-12 | University Of Colorado Foundation, Inc. | Culture media for mammalian cells |
AU2336592A (en) * | 1991-06-10 | 1993-01-12 | Research Development Foundation | Rb transferred cells and method |
EP0633934A1 (en) * | 1992-04-02 | 1995-01-18 | Imperial Cancer Research Technology Limited | Modified cells and method of treatment |
-
1993
- 1993-05-26 US US08/066,556 patent/US5550019A/en not_active Expired - Lifetime
-
1994
- 1994-05-26 JP JP50097895A patent/JP3704348B2/ja not_active Expired - Lifetime
- 1994-05-26 PT PT94919263T patent/PT751709E/pt unknown
- 1994-05-26 DE DE69428130T patent/DE69428130T3/de not_active Expired - Lifetime
- 1994-05-26 WO PCT/US1994/005980 patent/WO1994027426A1/en active IP Right Grant
- 1994-05-26 AT AT94919263T patent/ATE204704T1/de not_active IP Right Cessation
- 1994-05-26 DK DK94919263T patent/DK0751709T3/da active
- 1994-05-26 EP EP01107435A patent/EP1130087A3/en not_active Ceased
- 1994-05-26 CA CA2163439A patent/CA2163439C/en not_active Expired - Lifetime
- 1994-05-26 ES ES94919263T patent/ES2160124T3/es not_active Expired - Lifetime
- 1994-05-26 EP EP94919263A patent/EP0751709B2/en not_active Expired - Lifetime
-
1998
- 1998-11-06 US US09/188,066 patent/US6514761B1/en not_active Expired - Fee Related
-
2002
- 2002-09-09 JP JP2002263443A patent/JP3867033B2/ja not_active Expired - Lifetime
- 2002-11-01 US US10/285,853 patent/US7427495B2/en not_active Expired - Fee Related
-
2007
- 2007-10-09 US US11/869,634 patent/US7910370B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US7910370B2 (en) | 2011-03-22 |
US20030069201A1 (en) | 2003-04-10 |
PT751709E (pt) | 2001-12-28 |
JP2003176236A (ja) | 2003-06-24 |
WO1994027426A1 (en) | 1994-12-08 |
US7427495B2 (en) | 2008-09-23 |
ATE204704T1 (de) | 2001-09-15 |
US5550019A (en) | 1996-08-27 |
DE69428130T3 (de) | 2006-10-12 |
DE69428130T2 (de) | 2002-05-02 |
EP0751709B2 (en) | 2006-03-29 |
US20080102060A1 (en) | 2008-05-01 |
CA2163439A1 (en) | 1994-12-08 |
US6514761B1 (en) | 2003-02-04 |
ES2160124T3 (es) | 2001-11-01 |
JPH09502083A (ja) | 1997-03-04 |
EP0751709B1 (en) | 2001-08-29 |
EP1130087A3 (en) | 2003-10-29 |
JP3704348B2 (ja) | 2005-10-12 |
DE69428130D1 (de) | 2001-10-04 |
EP0751709A4 (en) | 1997-09-24 |
CA2163439C (en) | 2011-01-04 |
JP3867033B2 (ja) | 2007-01-10 |
EP1130087A2 (en) | 2001-09-05 |
EP0751709A1 (en) | 1997-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0751709T3 (da) | Anvendelse af Bcl-2 til fremstilling af lægemidler til terapeutisk behandling og forebyggelse af sygdomme | |
DK0517820T3 (da) | Anvendelse af 3-guanidinopropionsyre ved fremstillingen af et lægemiddel til behandling og hindring af overdreven fedme | |
DK0547952T3 (da) | Anvendelse af modafinil til fremstilling af et antiisskæmisk lægemiddel | |
DE69435243D1 (de) | Verwendung vom neurotoxischem Komponent von Botulinum Toxin zur Behandlung von Glattmuskelkrankheiten | |
NO307968B1 (no) | Pyrazolo- og pyrrolopyridiner og farmasøytisk blanding derav | |
DE69332732D1 (de) | Pharmazeutische Zusammensetzung und Methode zur Behandlung von Hyperlipidämie und Arterioskerose | |
DK3695A (da) | Fremgangsmåde og anlæg til behandling af biologiske fluider | |
NO891896L (no) | Fremgangsmaate og innretning for behandling av medisinsk spesialavfall. | |
DK140494A (da) | Fremgangsmåde og anlæg til behandling af overgangszonemateriale | |
DK0668763T3 (da) | Anvendelse af phenserin til fremstillingen af lægemidler til behandlingen af kognitive sygdomme | |
DK91793D0 (da) | Fremgangsmaade til overfladebehandling, midler til udoevelse og anvendelsen heraf | |
DE69532066D1 (de) | Arzneimittel zur Behandlung von Restenosis und Gefässsklerose | |
DK0655243T3 (da) | Melatoninderivater til anvendelse ved behandling af søvnlidelser | |
NO961226D0 (no) | Blandinger for forebyggelse og behandling av viralinduserte tumorer | |
NO993627L (no) | Anvendelse av en forbindelse for fremstilling av et legemiddel | |
ATE239470T1 (de) | Melatonin-derivate zur verwendung in der behandlung von desynchronisierungs-erkankungen | |
DK0594528T3 (da) | Fremgangsmåde og anlæg til behandling af halve slagtekroppe | |
DK0693912T3 (da) | Apparat til medicinsk behandling | |
DE69418931D1 (de) | Verwendung von VIP und deren Analogen und Fragmenten zur Behandlung von neurodegenerativen Krankheiten | |
DK0670721T3 (da) | Lægemiddel til behandling og forebyggelse af knogle- og ledsygdomme | |
EA199900862A1 (ru) | Способ лечения сосудистых нарушений | |
DE68909750D1 (de) | Vorrichtung zur therapeutischen behandlung von lumbago sowie lumbago/ischias. | |
DK0691957T3 (da) | (S)-alfa-phenyl-2-pyridinethanamin-(S)-malat og dets anvendelse som et medikament. | |
NO904873D0 (no) | Fremgangsmaate og anordning for behandling av sinkslig. | |
DK0707477T3 (da) | Anvendelse af Efaxoran og derivater deraf til fremstilling af lægemidler beregnet til behandling af neurodegenerative sygdo |